Clinical Trials
2 trialsNCT00386516 2017-08-01
Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer
Galectin Therapeutics Inc.
Phase 2 Withdrawn
NCT01859182 2014-09-09
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Withdrawn